How drug companies are playing hardball with Australia’s PBS

Drug companies are escalating their demands for higher prices for medications in Australia, putting pressure on the country's Pharmaceutical Benefits Scheme (PBS). The situation has reached a critical point, with several pharmaceutical firms threatening to withdraw their products from the market or refuse to seek PBS listings altogether. This tension highlights growing concerns over how Australia balances affordability and innovation in healthcare. Negotiations between drug manufacturers and the Australian government have increasingly turned contentious, particularly around the pricing of newer therapies. For instance, the future of certain multiple sclerosis treatments has become uncertain following disputes over cost. While these medications remain available through the PBS during a pending review, the standoff underscores broader challenges in maintaining access to essential medicines. Similarly, Eli Lilly recently stated it would not pursue PBS listing for its drug tirzepatide (Mounjaro) for type 2 diabetes after failing to reach agreement on pricing. This dispute reflects a global trend in which pharmaceutical companies are leveraging their influence to secure higher prices in key markets. The United States has long faced criticism for allowing high drug prices, with former President Donald Trump accusing other nations of pressuring American firms to accept lower rates. His comments highlighted a shift in U.S. policy toward protecting domestic pharmaceutical interests. Recently, the U.S.-UK trade deal signed in December 2025 marks a significant concession to this pressure. Under the agreement, the UK’s National Institute for Health and Care Excellence (NICE) is required to raise the prices it accepts for new drugs, while the National Health Service (NHS) must significantly increase its spending on new medications by 2036. Such measures have raised alarms among health officials. With the NHS already facing financial strain, additional funding for drugs could result in reduced resources for other healthcare services, potentially leading to up to 291,000 more deaths by 2036. Despite these concerns, NICE currently approves over 90% of new drug applications, suggesting that the changes may not necessarily expand access to innovative treatments but rather inflate costs. The process of introducing a new medication to the Australian market involves two main stages. First, the Therapeutic Goods Administration (TGA) must approve the drug based on clinical trials demonstrating its safety and efficacy. This evaluation typically compares the drug to a placebo or existing treatments, though it does not require the new therapy to be superior, only that it is not inferior. Following approval, the company seeks PBS listing, where the Pharmaceutical Benefits Advisory Committee assesses the drug’s value in terms of health outcomes, such as improved quality of life or prevention of complications. Price negotiations extend beyond mere financial considerations. The committee evaluates whether a new drug offers meaningful health benefits compared to current treatments. Studies analyzing over 1,000 drug approvals in France revealed that approximately half of these medications showed no improvement over existing options. In such cases, the allowable price is capped at levels comparable to current treatments, ensuring cost-effectiveness. Advocacy groups have expressed frustration over the evolving landscape. Felicity McNeill, chair of Better Access Australia, noted that historically, pharmaceutical companies accepted Australia’s pricing model due to the country’s relatively limited healthcare budget. However, she pointed out that Australia spends about A$1,250 per person annually on prescription and over-the-counter medications, placing it eighth globally in spending. This suggests that Australia is far from being a “charity case,” yet the ongoing tensions indicate a complex interplay between economic pressures and public health priorities. As negotiations continue, the implications for patients and healthcare systems remain unclear. The outcome of these disputes will likely shape the availability and affordability of essential medications in the years ahead.